NKTR-214 (NEKTAR) A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer (Aktiv)
XL184-021 Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors (Aktiv)
Zweitlinie oder später
BI 1403-0011 - BRIGHTLINE-2 Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of Brigimadlin (BI 907828) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours (Aktiv)
Basilea DZB-CS-201 (FIDES-02) Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer (Aktiv)